Esperion’s Nexletol Approved for Lowering Cholesterol

Esperion’s Nexletol (bempedoic acid) earned FDA approval as an oral, once-daily, non-statin LDL-cholesterol lowering medicine.

Nexletol is indicated as an adjunct to diet and statin therapy to treat adults with hypercholesterolemia or atherosclerotic cardiovascular disease who need additional lowering of LDL-C.

The approval was based on positive results from a phase 3 study in more than 3,000 patients that showed an average of 18 percent lower LDL cholesterol when Nexletol was administered along with statins.